AKT1 and prostate carcinoma: The PI3K-Akt signaling pathway is a key oncogenic pathway and plays a pivotal role in cancer progression, drug resistance, and treatment in various cancer types [40, 41], and its constitutive activation due to loss of PTEN in most advanced prostate cancer cases contributes to resistance to androgen deprivation therapy [42, 43].